InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...
InMed Pharmaceuticals: InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a ...
InMed advances AMD treatment with promising IVT drug formulation
VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ: INM), a small-cap biotech company with a market capitalization of $2.21 million, has announced the selection of an intravitreal (IVT) formulation, ...
Healio7h
VIDEO: NT-501 for macular telangiectasia nears PDUFA date
In this Healio Video Perspective from Hawaiian Eye 2025, Richard Small, CEO of Neurotech Pharmaceuticals, discusses the ...